Rutherford Cross has partnered with NeuroClin to recruit a Head of Finance, Planning & Analysis to be based at its office at Eurocentral, Lanarkshire.
NeuroClin, formerly known as the Glasgow Memory Clinic, was founded in 1999 as an independent research organisation participating in national and international studies aimed at developing better treatments for Memory Impairment, Alzheimer’s disease and Dementia. Since 2010, NeuroClin has expanded its research portfolio to include a broader range of neurological conditions, including Parkinson’s disease, Huntington’s disease, PSP, Anxiety and Depression.
Clinical studies remain the only way to test new potential treatments for neurological disorders, and NeuroClin is at the forefront of this work. Through decades of Alzheimer’s research, NeuroClin and its trusted partners have developed deep expertise across early detection, diagnosis and treatment – including the use of newly approved disease modifying therapies that are not yet available in the NHS. Building on this capability, a new Private Testing, Diagnosis and Treatment service (“Private Treatment”) was launched in 2025 to complement the Clinic’s established research activity.
Both research and private treatment services are delivered from state of the art facilities at Excel House, Eurocentral, and Muir House, Warrington. The teams comprise experienced healthcare professionals dedicated to the research and treatment of neurological diseases. Now backed by private equity partners Foresight Group, Fullbrook Thorpe and N4 Partners, NeuroClin has ambitious plans to diversify further and build on the growing private treatment opportunity.
This role will lead the Financial Planning and Analysis (FP&A) function and will be instrumental in driving the company’s growth strategy as it expands beyond its core clinical research operations into new therapeutic areas, geographies, and service lines—including private treatment offerings. The position will provide strategic financial leadership, guide investment decisions, and ensure long-term financial sustainability across both the research and treatment divisions. The role will report directly to the CFO – Kirsty Blair.
NeuroClin is an equal opportunities employer and positively encourages applications from suitably qualified and eligible candidates regardless of sex, race, disability, age, sexual orientation, gender reassignment, religion or belief, marital status or pregnancy and maternity.
All third-party applications, enquiries and direct approaches to NeuroClin will be referred to Rutherford Cross for review and assessment.
For full details on this opportunity please see the link below and get in contact with Hazel Wynn if you are keen to discuss further: [email protected].
Neuroclin – Head of Finance, Planning & Analysis – click to open
 |
